NO20032425L - Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former - Google Patents

Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former

Info

Publication number: NO20032425L
Authority: NO; Norway
Prior art keywords: forms; new; preparing; processes; preparation
Prior art date: 2000-11-30

Application number

NO20032425A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032425D0 (no

Inventor

Judith Aronhime

Ramy Lidor-Hadas

Valerie Niddam

Revital Lifshitz

Eti Ishai

Guy Sambursky

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-30

Filing date

2003-05-28

Publication date

2003-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27540285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032425(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-28 Application filed by Teva Pharma filed Critical Teva Pharma

2003-05-28 Publication of NO20032425D0 publication Critical patent/NO20032425D0/no

2003-07-25 Publication of NO20032425L publication Critical patent/NO20032425L/no

Links

238000000034 method Methods 0.000 title 2
FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title 1
239000013078 crystal Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pyrrole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20032425A 2000-11-30 2003-05-28 Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former NO20032425L (no)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US25007200P	2000-11-30	2000-11-30
US26789701P	2001-02-09	2001-02-09
US28187201P	2001-04-05	2001-04-05
US31214401P	2001-08-13	2001-08-13
US32652901P	2001-10-01	2001-10-01
PCT/US2001/044636 WO2002043732A1 (fr)	2000-11-30	2001-11-29	Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et leurs procedes de preparation, et nouveaux procedes de preparation d'autres formes

Publications (2)

Publication Number	Publication Date
NO20032425D0 NO20032425D0 (no)	2003-05-28
NO20032425L true NO20032425L (no)	2003-07-25

Family

ID=27540285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032425A NO20032425L (no)	2000-11-30	2003-05-28	Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former

Country Status (23)

Country	Link
US (15)	US20020183378A1 (fr)
EP (5)	EP2194041A1 (fr)
JP (2)	JP2004514694A (fr)
KR (1)	KR100765871B1 (fr)
CN (1)	CN1489463A (fr)
AU (1)	AU2002217927A1 (fr)
BG (1)	BG107856A (fr)
BR (1)	BR0115892A (fr)
CA (3)	CA2625277A1 (fr)
CZ (1)	CZ20031766A3 (fr)
DE (1)	DE01998348T1 (fr)
ES (2)	ES2215495T1 (fr)
HR (2)	HRP20130545A2 (fr)
HU (1)	HUP0600538A3 (fr)
IL (2)	IL156055A0 (fr)
IS (1)	IS6829A (fr)
MX (1)	MXPA03004844A (fr)
NO (1)	NO20032425L (fr)
PL (1)	PL363228A1 (fr)
SK (1)	SK8062003A3 (fr)
TR (1)	TR200400815T3 (fr)
WO (1)	WO2002043732A1 (fr)
YU (1)	YU42803A (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE36268E (en) *	1988-03-15	1999-08-17	Boehringer Mannheim Corporation	Method and apparatus for amperometric diagnostic analysis
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
PL362472A1 (en) *	2000-11-03	2004-11-02	Teva Pharma	Atorvastatin hemi-calcium form vii
IL155890A0 (en) *	2000-11-16	2003-12-23	Teva Pharma	HYDROLYSIS OF [R(R,R)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (ko)	2000-12-27	2008-01-03	테바 파마슈티컬 인더스트리즈 리미티드	아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
EP1423364B1 (fr) *	2001-06-29	2015-11-04	Warner-Lambert Company LLC	Formes cristallines de sel hemicalcique (2:1) d'acide [r-(r,r)] -2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl -1h-pyrrole-1-heptanoique (atorvastatine)
JP2005500351A (ja) *	2001-07-30	2005-01-06	ドクター・レディーズ・ラボラトリーズ・リミテッド	結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
US7074818B2 (en)	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
IL160077A0 (en) *	2001-08-16	2004-06-20	Teva Pharma	Processes for preparing calcium salt forms of statins
CZ296967B6 (cs) *	2002-02-01	2006-08-16	Zentiva, A.S.	Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
WO2003070702A1 (fr) *	2002-02-15	2003-08-28	Teva Pharmaceutical Industries Ltd.	Nouvelles formes cristallines d'hemi-calcium d'atorvastatine
IL163594A0 (en)	2002-02-19	2005-12-18	Teva Pharma	Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
AU2002356423A1 (en) *	2002-05-28	2003-12-12	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
EP1562583A1 (fr) *	2002-09-03	2005-08-17	Morepen Laboratories Ltd.	Forme vi de calcium d'atorvastatine ou hydrates de cette derniere
EP1424324A1 (fr) *	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
CA2508871C (fr) *	2002-11-28	2008-09-09	Teva Pharmaceutical Industries Ltd.	Forme cristalline f de sel d'hemi-calcium d'astorvastatine
BRPI0410840A (pt)	2003-05-30	2006-07-04	Ranbaxy Lab Ltd	derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
US7790197B2 (en)	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US20050271717A1 (en)	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
US7655692B2 (en)	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
ITMI20032144A1 (it) *	2003-11-07	2005-05-08	Alfa Wassermann Spa	Forme polimorfe di rifaximina, processi per ottenerle e
CA2456430A1 (fr) *	2004-01-28	2005-07-28	Brantford Chemicals Inc.	Procede ameliore pour la preparation d'atorvastatine calcique amorphe
SI1727795T1 (sl)	2004-03-17	2012-05-31	Ranbaxy Lab Ltd	Postopek za pripravo atorvastatin kalcija v amorfni obliki
EP1745020A2 (fr)	2004-05-05	2007-01-24	Pfizer Products Incorporated	Formes salines d'acide ¬r-(r, r)\|-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-¬(phenylamino)carbonyl\|-1h-pyrrole-1-heptanoique
US20080262074A1 (en) *	2004-05-24	2008-10-23	Pfizer, Inc.	Salt Forms of [R-(R,R)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
RU2412191C2 (ru) *	2004-07-16	2011-02-20	Лек Фармасьютиклз Д.Д.	Продукты окислительной деструкции кальций аторвастатина
MX2007000765A (es) *	2004-07-20	2007-03-28	Warner Lambert Co	Formas cristalinas de sal de calcio del acido (r-(r, r))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
ES2262459T1 (es) *	2004-07-22	2006-12-01	Teva Pharmaceutical Industries Ltd	Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion.
EP1694685A1 (fr) *	2004-09-28	2006-08-30	Teva Pharmaceutical Industries Ltd	Procede pour la preparation de formes du sel de calcium de l'atorvastatine substantiellement libres d'impuretees
JP2008514722A (ja) *	2004-09-30	2008-05-08	ドクターレディズラボラトリーズリミテッド	非結晶性アトルバスタチンカルシウム
MX2007004425A (es) *	2004-10-18	2007-06-07	Teva Pharma	Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
KR20070067175A (ko)	2004-10-28	2007-06-27	워너-램버트 캄파니 엘엘씨	무정형 아토르바스타틴 형성 방법
WO2006048894A1 (fr) *	2004-11-05	2006-05-11	Morepen Laboratories Limited	Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
CA2588216A1 (fr) *	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Formulations d'atorvastatine stables
PT1698630E (pt)	2005-03-03	2014-09-15	Alfa Wassermann Spa	Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
RU2409563C2 (ru) *	2005-04-08	2011-01-20	Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг	Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина
US20070032665A1 (en) *	2005-08-04	2007-02-08	Srinivasulu Gudipati	Preparation of atorvastatin calcium form i
ES2270722B1 (es) *	2005-09-15	2008-03-01	Ercros Industrial, S.A.	Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) *	2005-09-16	2009-08-27	Yatendra Kumar	Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (fr)	2005-09-21	2007-03-21	Renuka D. Reddy	Procede de recuit de l'atorvastatine amorphe
JP2009514851A (ja)	2005-11-08	2009-04-09	ランバクシーラボラトリーズリミテッド	（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
EP1923057A1 (fr)	2005-11-21	2008-05-21	Teva Pharmaceutical Industries Ltd	Formule pharmaceutique atorvastanine
EP1808162A1 (fr)	2005-11-21	2007-07-18	Teva Pharmaceutical Industries Ltd.	Formulation pharmacéutique de l'Atorvastatin
DE602006014193D1 (de)	2005-11-21	2010-06-17	Warner Lambert Co	Neue formen von är-(r,r)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium
MX2007014329A (es) *	2005-12-13	2008-03-19	Teva Pharma	Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
EP1810667A1 (fr)	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique contenant de l'atorvastatin amorphé
JP2007246514A (ja) *	2006-02-14	2007-09-27	Toyama Chem Co Ltd	ピペラシリンナトリウムの新規な結晶
US20090240064A1 (en) *	2006-02-22	2009-09-24	Venkata Panakala Rao Gogulapati	Crystalline form of atorvastatin hemi-calcium
EP1877375A1 (fr) *	2006-03-01	2008-01-16	Teva Pharmaceutical Industries Ltd	Procede de preparation d'une forme cristalline d'hemi-calcium d'atorvastatine
US20070265456A1 (en) *	2006-05-09	2007-11-15	Judith Aronhime	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN100406438C (zh) *	2006-06-30	2008-07-30	浙江新东港药业股份有限公司	一种无定型阿伐他汀钙的制备方法
MX2009000439A (es) *	2006-07-14	2009-02-04	Ranbaxy Lab Ltd	Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
AU2007300071A1 (en) *	2006-09-27	2008-04-03	Dr. Reddy's Laboratories Ltd.	Atorvastatin pharmaceutical compositions
US20100113802A1 (en) *	2006-11-02	2010-05-06	Cadila Pharmaceuticals Limited	Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) *	2007-01-24	2010-11-16	Apotex Pharmachem Inc.	Atorvastatin calcium propylene glycol solvates
US20100063273A1 (en) *	2007-01-31	2010-03-11	Toyama Chemical Co., Ltd	Novel crystal of piperacillin sodium
KR101012917B1 (ko)	2007-03-02	2011-02-08	동아제약주식회사	피롤 헵탄산 화합물의 신규한 결정형
WO2008129562A2 (fr) *	2007-04-20	2008-10-30	Morepen Laboratories Limited	Procédé amélioré pour la préparation d'atorvastatine amorphe hémicalcique stable et de ses sels
EP2182925A2 (fr) *	2007-07-27	2010-05-12	Cipla Limited	Compositions pharmaceutiques et leur procédé de préparation
WO2009082362A1 (fr) *	2007-11-05	2009-07-02	Ulkar Kimya San. Ve Tic. A.S.	Procédé de procution de statines sous forme pure
EP2075246A1 (fr)	2007-12-27	2009-07-01	M. J. Institute of Research	Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine
CN101538237B (zh) *	2008-05-30	2011-04-06	天津和美生物技术有限公司	阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用
NZ591184A (en)	2008-07-17	2012-09-28	Delaval Holding Ab	Method of cleaning food and beverage manufacturing and handling equipmemt
WO2011028309A1 (fr)	2009-09-04	2011-03-10	University Of Toledo	Procédés de fabrication de bêta-lactones optiquement pures à partir d'aldéhydes et compositions obtenues par ces procédés
US11473032B2 (en)	2010-02-02	2022-10-18	Fuchs Petrolub Se	Constant velocity joint having a boot
IT1398550B1 (it)	2010-03-05	2013-03-01	Alfa Wassermann Spa	Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20120011249A (ko)	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
ITBO20120368A1 (it)	2012-07-06	2014-01-07	Alfa Wassermann Spa	Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN102766136A (zh) *	2012-08-07	2012-11-07	浙江宏元药业有限公司	一种制备阿托伐他汀钙中间体的方法
AU2014348523B2 (en)	2013-11-15	2019-01-03	Akebia Therapeutics, Inc.	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN105111123A (zh) *	2013-11-25	2015-12-02	李兴惠	阿托伐他汀钙及组合物
CN104945300B (zh) *	2015-06-17	2017-05-10	北京嘉林药业股份有限公司	一种ⅰ型阿托伐他汀钙的纯化方法
CN104983690A (zh) *	2015-08-18	2015-10-21	青岛蓝盛洋医药生物科技有限责任公司	一种治疗冠心病的药物阿托伐他汀钙组合物干混悬剂
EP3272336A1 (fr) *	2016-07-19	2018-01-24	Stada Arzneimittel Ag	Composition d'atorvastatine
WO2025147589A1 (fr)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US99224A (en) *		1870-01-25		Improvement in pocket-sates for friction-matches
US115709A (en) *		1871-06-06		Improvement in curriers slickers
US2598627A (en) *	1949-10-11	1952-05-27	Robert Gair Co Inc	Folding carton
DE2748825C2 (de) *	1976-11-02	1986-11-27	Sankyo Co., Ltd., Tokio/Tokyo	Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en)	1988-02-22	1991-03-26	Warner-Lambert Company	Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
SG45369A1 (en) *	1993-01-19	1998-10-16	Warner Lambert Co	Stable oral ci-981 formulation and process of preparing same
US5298627A (en)	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE4411536A1 (de) *	1994-04-02	1995-10-05	Cassella Ag	Wasserquellbare hydrophile Polymere
DE69634054T2 (de) *	1995-07-17	2005-12-08	Warner-Lambert Co.	Kristalline (R-(R, R))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin)
HRP960313B1 (en)	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en)	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) *	1996-07-16	2000-07-11	Warner-Lambert Company	Process for the production of amorphous [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6065729A (en) *	1998-01-28	2000-05-23	Prince Corporation	Slide-out container holder
US5959156A (en)	1998-11-12	1999-09-28	Bp Amoco Corporation	Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether
IN191236B (fr) *	1999-05-25	2003-10-11	Ranbaxy Lab Ltd
HU226640B1 (en) *	1999-10-18	2009-05-28	Egis Gyogyszergyar Nyilvanosan	Process for producing amorphous atorvastatin calcium salt
US7411075B1 (en) *	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
SI1535613T1 (sl) *	1999-11-17	2010-12-31	Teva Pharma	Postopek za pripravo polimorfne oblike atorvastatin kalcija
SI20425A (sl) *	1999-12-10	2001-06-30	LEK tovarna farmacevtskih in kemi�nih izdelkov d.d.	Priprava amorfnega atorvastatina
IL149087A0 (en)	1999-12-17	2002-11-10	Warner Lambert Res & Dev Ie	A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium
ATE320415T1 (de) *	1999-12-17	2006-04-15	Pfizer Science & Tech Ltd	Verfahren zur herstellung von kristallin atorvastin kalcium
PL362472A1 (en) *	2000-11-03	2004-11-02	Teva Pharma	Atorvastatin hemi-calcium form vii
IL155890A0 (en) *	2000-11-16	2003-12-23	Teva Pharma	HYDROLYSIS OF [R(R,R)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) *	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (ko) *	2000-12-27	2008-01-03	테바 파마슈티컬 인더스트리즈 리미티드	아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US6476235B2 (en)	2001-01-09	2002-11-05	Warner-Lambert Company	Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (fr)	2001-01-17	2002-07-25	Biocon India Limited	Atorvastatine calcique
WO2002057229A1 (fr)	2001-01-19	2002-07-25	Biocon India Limited	FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R,R)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl)	2001-01-23	2002-08-31	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Priprava amorfnega atorvastatina
SI20848A (sl) *	2001-03-14	2002-10-31	Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.	Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (fr)	2001-04-11	2003-08-09	Cadila Heathcare Ltd
EP1423364B1 (fr)	2001-06-29	2015-11-04	Warner-Lambert Company LLC	Formes cristallines de sel hemicalcique (2:1) d'acide [r-(r,r)] -2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl -1h-pyrrole-1-heptanoique (atorvastatine)
JP2005500351A (ja)	2001-07-30	2005-01-06	ドクター・レディーズ・ラボラトリーズ・リミテッド	結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
US7074818B2 (en) *	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
IL160077A0 (en) *	2001-08-16	2004-06-20	Teva Pharma	Processes for preparing calcium salt forms of statins
WO2003018547A2 (fr)	2001-08-31	2003-03-06	Morepen Laboratories Ltd.	Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)
US7141662B2 (en)	2001-11-30	2006-11-28	University Of Maryland, Baltimore	Nucleic acids encoding novel proteins in enteroaggregative Escherichia coli (EAEC)
UA77990C2 (en) *	2001-12-12	2007-02-15		Crystalline calcium salt of (2:1) [r-(r,r)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
WO2003070702A1 (fr)	2002-02-15	2003-08-28	Teva Pharmaceutical Industries Ltd.	Nouvelles formes cristallines d'hemi-calcium d'atorvastatine
IL163594A0 (en)	2002-02-19	2005-12-18	Teva Pharma	Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
JP4364650B2 (ja)	2002-03-28	2009-11-18	イーエムシーコーポレイション	データ記憶システム
AU2002356423A1 (en) *	2002-05-28	2003-12-12	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
EP1562583A1 (fr) *	2002-09-03	2005-08-17	Morepen Laboratories Ltd.	Forme vi de calcium d'atorvastatine ou hydrates de cette derniere
SI21302A (sl)	2002-10-11	2004-04-30	LEK farmacevtska dru�ba d.d.	Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
CA2508871C (fr)	2002-11-28	2008-09-09	Teva Pharmaceutical Industries Ltd.	Forme cristalline f de sel d'hemi-calcium d'astorvastatine
EP1424324A1 (fr)	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
US20040242670A1 (en) *	2003-06-02	2004-12-02	Sonny Sebastian	Process for preparation of amorphous atorvastatin calcium
ES2262459T1 (es) *	2004-07-22	2006-12-01	Teva Pharmaceutical Industries Ltd	Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion.
MX2007004425A (es) *	2004-10-18	2007-06-07	Teva Pharma	Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
US20070032665A1 (en) *	2005-08-04	2007-02-08	Srinivasulu Gudipati	Preparation of atorvastatin calcium form i

2001
- 2001-10-29 IL IL15605501A patent/IL156055A0/xx unknown
- 2001-11-29 MX MXPA03004844A patent/MXPA03004844A/es active IP Right Grant
- 2001-11-29 CA CA002625277A patent/CA2625277A1/fr not_active Abandoned
- 2001-11-29 BR BR0115892-9A patent/BR0115892A/pt not_active IP Right Cessation
- 2001-11-29 KR KR1020037007298A patent/KR100765871B1/ko not_active Expired - Fee Related
- 2001-11-29 EP EP10151206A patent/EP2194041A1/fr not_active Withdrawn
- 2001-11-29 EP EP10152443A patent/EP2192113A1/fr not_active Withdrawn
- 2001-11-29 SK SK806-2003A patent/SK8062003A3/sk unknown
- 2001-11-29 AU AU2002217927A patent/AU2002217927A1/en not_active Abandoned
- 2001-11-29 EP EP06024449A patent/EP1783113A3/fr not_active Ceased
- 2001-11-29 HR HRP20130545AA patent/HRP20130545A2/hr not_active Application Discontinuation
- 2001-11-29 DE DE0001363621T patent/DE01998348T1/de active Pending
- 2001-11-29 JP JP2002545702A patent/JP2004514694A/ja active Pending
- 2001-11-29 CA CA2689915A patent/CA2689915A1/fr not_active Abandoned
- 2001-11-29 CN CNA018223400A patent/CN1489463A/zh active Pending
- 2001-11-29 HU HU0600538A patent/HUP0600538A3/hu unknown
- 2001-11-29 CA CA002429590A patent/CA2429590C/fr not_active Expired - Fee Related
- 2001-11-29 HR HR20030523A patent/HRP20030523A2/hr not_active Application Discontinuation
- 2001-11-29 TR TR2004/00815T patent/TR200400815T3/xx unknown
- 2001-11-29 ES ES01998348T patent/ES2215495T1/es active Pending
- 2001-11-29 YU YU42803A patent/YU42803A/sh unknown
- 2001-11-29 EP EP10151205.1A patent/EP2192112B1/fr not_active Expired - Lifetime
- 2001-11-29 WO PCT/US2001/044636 patent/WO2002043732A1/fr not_active Ceased
- 2001-11-29 PL PL01363228A patent/PL363228A1/xx not_active Application Discontinuation
- 2001-11-29 ES ES10151205.1T patent/ES2437157T3/es not_active Expired - Lifetime
- 2001-11-29 CZ CZ20031766A patent/CZ20031766A3/cs unknown
- 2001-11-29 EP EP01998348A patent/EP1363621A4/fr not_active Ceased
- 2001-11-29 US US09/997,126 patent/US20020183378A1/en not_active Abandoned
2003
- 2003-05-21 IL IL156055A patent/IL156055A/en not_active IP Right Cessation
- 2003-05-27 IS IS6829A patent/IS6829A/is unknown
- 2003-05-28 NO NO20032425A patent/NO20032425L/no not_active Application Discontinuation
- 2003-05-29 BG BG107856A patent/BG107856A/xx unknown
2004
- 2004-07-28 US US10/901,845 patent/US6992194B2/en not_active Expired - Fee Related
- 2004-11-19 US US10/994,142 patent/US7144916B2/en not_active Expired - Fee Related
2005
- 2005-07-29 US US11/193,089 patent/US7256212B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,674 patent/US7456297B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,707 patent/US7151183B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/193,112 patent/US7189861B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,672 patent/US7161012B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,828 patent/US7488750B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,815 patent/US20060106232A1/en not_active Abandoned
- 2005-10-24 US US11/257,886 patent/US20060100267A1/en not_active Abandoned
- 2005-10-24 US US11/257,808 patent/US20060106231A1/en not_active Abandoned
- 2005-10-24 US US11/257,979 patent/US7468444B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,821 patent/US7342120B2/en not_active Expired - Fee Related
2007
- 2007-10-23 US US11/977,387 patent/US20080214650A1/en not_active Abandoned
2009
- 2009-03-11 JP JP2009058477A patent/JP2009120624A/ja active Pending

Also Published As

Publication number	Publication date
IL156055A0 (en)	2003-12-23
ES2437157T3 (es)	2014-01-09
HUP0600538A3 (en)	2010-09-28
BR0115892A (pt)	2003-10-28
US20050090542A1 (en)	2005-04-28
US7342120B2 (en)	2008-03-11
EP2192112A1 (fr)	2010-06-02
NO20032425D0 (no)	2003-05-28
TR200400815T3 (tr)	2004-07-21
KR20030059297A (ko)	2003-07-07
US7256212B2 (en)	2007-08-14
SK8062003A3 (en)	2004-07-07
US20050282885A1 (en)	2005-12-22
WO2002043732A1 (fr)	2002-06-06
AU2002217927A1 (en)	2002-06-11
US7488750B2 (en)	2009-02-10
HUP0600538A2 (en)	2006-09-28
ES2215495T1 (es)	2004-10-16
MXPA03004844A (es)	2005-04-19
JP2004514694A (ja)	2004-05-20
EP2192112B1 (fr)	2013-08-28
DE01998348T1 (de)	2004-08-26
US20060106231A1 (en)	2006-05-18
US20050261359A1 (en)	2005-11-24
US7161012B2 (en)	2007-01-09
HRP20030523A2 (en)	2005-06-30
US7456297B2 (en)	2008-11-25
CA2429590C (fr)	2008-06-10
EP2192113A1 (fr)	2010-06-02
EP2194041A1 (fr)	2010-06-09
YU42803A (sh)	2006-05-25
US20060058533A1 (en)	2006-03-16
US20050261360A1 (en)	2005-11-24
EP1363621A1 (fr)	2003-11-26
CA2625277A1 (fr)	2002-06-06
HRP20130545A2 (hr)	2013-11-08
US20060100267A1 (en)	2006-05-11
JP2009120624A (ja)	2009-06-04
IL156055A (en)	2010-12-30
CN1489463A (zh)	2004-04-14
US20060100446A1 (en)	2006-05-11
EP1363621A4 (fr)	2005-12-28
CA2429590A1 (fr)	2002-06-06
PL363228A1 (en)	2004-11-15
US7468444B2 (en)	2008-12-23
US20050004206A1 (en)	2005-01-06
BG107856A (en)	2004-11-30
US20050267198A1 (en)	2005-12-01
US7151183B2 (en)	2006-12-19
CZ20031766A3 (cs)	2004-08-18
KR100765871B1 (ko)	2007-10-11
US20060106232A1 (en)	2006-05-18
US7189861B2 (en)	2007-03-13
US20020183378A1 (en)	2002-12-05
IS6829A (is)	2003-05-27
US20080214650A1 (en)	2008-09-04
CA2689915A1 (fr)	2002-06-06
EP1783113A2 (fr)	2007-05-09
EP1783113A3 (fr)	2007-05-30
US6992194B2 (en)	2006-01-31
US20060100445A1 (en)	2006-05-11
US7144916B2 (en)	2006-12-05
US20050261361A1 (en)	2005-11-24

Publication	Publication Date	Title
NO20032425L (no)	2003-07-25	Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former
IS7188A (is)	2004-03-18	Asabísýklísk-setin samtengd heteróarýl efnasambönd, aðferð til framleiðslu þeirra og notkun
NO20043842L (no)	2004-09-14	Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX
NO20041994L (no)	2004-05-14	Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser
IS7261A (is)	2004-05-13	N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
NO20035193D0 (no)	2003-11-21	Nye pyrrolderivater som farmasöytiske midler
NO20040356L (no)	2004-03-19	Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
NO20024623L (no)	2002-11-08	Ny fremgangsmÕte for fremstilling av kondensert imidazopyridinderivat og ny krystallform
NO20023400D0 (no)	2002-07-15	Nye forbindelser med lipid- og kolesterolnedsettende virkning, fremgangsmåte ved deres fremstilling og farmasöytiskpreparat
NO20040292L (no)	2004-03-19	Fremgangsmate for fremstilling av 4-aminodifenylamin
NO20054876D0 (no)	2005-10-21	Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
WO2002030870A3 (fr)	2003-10-02	Derives de c-cyclohexylmethylamine substitues
NO20023662D0 (no)	2002-08-01	Nye heterocykliske derivater, fremgangsmåte ved fremstilling og farmasöytiske sammensetninger inneholdende det samme
NO20010522L (no)	2001-08-01	Nye piperidin-4-sulfonamidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
NO20026154D0 (no)	2002-12-20	Nye substituerte ftalider, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20013735D0 (no)	2001-07-30	Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner
NO20035633D0 (no)	2003-12-17	Teknisk syntesemetode for fremstilling av tropenol
NO20031844D0 (no)	2003-04-24	Nye askorbinsyreforbindelser, syntesemetoder og anvendelse derav
NO20023345D0 (no)	2002-07-11	Nye oktahydro-2H-pyrido[1-2-a]pyrazinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiskesammensetninger inneholdende dem
IS7008A (is)	2003-10-30	Nýjar píperidínkarboxamíð afleiður, aðferð til framleiðslu þeirra og lyfjasamsetningar sem innihalda þær
NO20021198L (no)	2002-09-13	Nye isoindoloindolonforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20016069D0 (no)	2001-12-12	Nye bicykliske amino-pyrazinonforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
NO20044332L (no)	2005-01-17	Forbedret fremgangsmate for fremstilling av nevirapine
NO20021330D0 (no)	2002-03-18	Nye indenoindolonforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20020308D0 (no)	2002-01-21	Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten

Legal Events

Date	Code	Title	Description
2006-07-03	FC2A	Withdrawal, rejection or dismissal of laid open patent application